Skip to main content
. Author manuscript; available in PMC: 2010 Dec 14.
Published in final edited form as: Clin Cancer Res. 2009 Dec 15;15(24):7711–7718. doi: 10.1158/1078-0432.CCR-09-2074

Fig 1.

Fig 1

Progression-free survival (PFS) and overall survival (OS) in melanoma patients treated with temozolomide and sorafenib. (A–B): Kaplan-Meier curves for (A) PFS and (B) OS; Arm A (Blue):patients without brain metastases or prior temozolomide, treated with extended dosing temozolomide (EDT) Arm B (orange); patients without brain metastases or prior temozolomide treated with standard dosing temozolomide (STD), Arm C (red) Patients with prior temozolomide, EDT Arm D (green) patients with brain metastases,,without prior temozolomide, SDT: Dots: censored patients.